RedHill Biopharma (RDHL, Financial) has been notified by the Nasdaq Stock Market's Listing Qualifications Department about its non-compliance with Nasdaq Listing Rule 5550. This rule mandates that companies on the Nasdaq Capital Market maintain at least $2,500,000 in stockholders’ equity to remain listed. According to RedHill's recently filed Annual Report on Form 20-F for the fiscal year ending December 31, 2024, the company reported a troubling stockholders’ deficit of $4,683,000.
This deficit places RedHill below the required threshold, and the company also fails to meet alternative criteria such as the market value of listed securities or net income from ongoing operations. In response to the notification, RedHill is actively considering various strategies to address the deficit and restore compliance, with the goal of preserving its listing on the Nasdaq Capital Market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Redhill Biopharma Ltd (RDHL, Financial) is $19,000.00 with a high estimate of $19,000.00 and a low estimate of $19,000.00. The average target implies an upside of 859,628.51% from the current price of $2.21. More detailed estimate data can be found on the Redhill Biopharma Ltd (RDHL) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Redhill Biopharma Ltd's (RDHL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Redhill Biopharma Ltd (RDHL, Financial) in one year is $1.63, suggesting a downside of 26.24% from the current price of $2.21. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Redhill Biopharma Ltd (RDHL) Summary page.
